[SCHEDULE 13G] Teva Pharmaceutical Industries Limited American SEC Filing

Rhea-AI Filing Summary

Phoenix Financial Ltd., an Israeli financial group, has filed a Schedule 13G declaring 57,383,157.61 ordinary shares of Teva Pharmaceutical Industries (TEVA), including 38.0 million ADSs. The position equals 5.0 % of Teva’s 1.147 billion shares outstanding as of 15 Jul 2025, triggering the 5 % reporting threshold.

The holding is purely passive under Rule 13d-1(b). Phoenix reports 0 sole voting/dispositive power; all powers are shared among independent subsidiaries that manage insurance, pension, provident and mutual-fund assets. Largest block: 42.17 million shares (3.68 %) held by “Partnership for Israeli Shares,” with smaller stakes across trust funds (1.08 %), “nostro” accounts (0.19 %), pension/provident funds (0.03 %) and linked insurance policies (0.02 %).

Phoenix disclaims any intent to influence Teva’s control or strategy and certifies the investment was made in the ordinary course. While the disclosure introduces a substantial Israeli institutional owner, it does not immediately affect Teva’s governance, capital structure or earnings outlook.

Positive

• Institutional confidence: Phoenix Financial’s 5 % stake adds a sizable, long-term Israeli investor to TEVA’s shareholder roster.

Negative

• None.

Insights

Securities Analyst

TL;DR Passive 5 % stake by Phoenix adds institutional support but has limited near-term impact on TEVA valuation.

Crossing the 5 % threshold makes Phoenix a reportable holder; however, its certification under Rule 13d-1(b) and shared, not sole, voting power confirm a non-activist stance. The purchase modestly widens Teva’s investor base, signaling confidence from a major Israeli insurer, yet does not alter fundamentals, cash flow or leverage. For investors, the filing is noteworthy for ownership monitoring but is unlikely to move the stock absent future activism or stake increases.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Teva Pharmaceutical Industries Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 0.10 per share

(Title of Class of Securities)

881624209

(CUSIP Number)

07/14/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 881624209

1

Names of Reporting Persons

Phoenix Financial Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 57,383,157.61
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 57,383,157.61

9

Aggregate Amount Beneficially Owned by Each Reporting Person

57,383,157.61

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: With regard to rows (6), (8), (9) and (11), the beneficial ownership of the securities reported herein is described in Item 4(a). With regard to rows (6), (8), and (9), the amount of shares includes 38,000,044 Ordinary Shares held in 38,000,044 of the issuer's American depositary shares ("ADSs"). Each ADS represents one Ordinary Share Row (11) is Based on 1,146,838,689 Ordinary Shares outstanding as of July 15, 2025 (as reported on Bloomberg LP).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Teva Pharmaceutical Industries Ltd
(b)	Address of issuer's principal executive offices: 124 Dvora HaNevi'a Street, Tel Aviv, Israel, 6944020
Item 2.
(a)	Name of person filing: Phoenix Financial Ltd. The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of Phoenix Financial Ltd. (the "Subsidiaries"). The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.
(b)	Address or principal business office or, if none, residence: The address of the Phoenix Financial Ltd. is Derech Hashalom 53, Givataim, 53454, Israel.
(c)	Citizenship: Phoenix Financial Ltd. - Israel
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.10 per share
(e)	CUSIP No.: 881624209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See row 9 of cover page of each reporting person. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group. In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement. As of July 14, 2025, the securities reported herein were held as follows: 12,408,067.41 ordinary shares (representing 1.08% of the total ordinary shares outstanding) beneficially owned by The Phoenix Investments House - trust funds. 2,169,705 ordinary shares (representing 0.19% of the total ordinary shares outstanding) beneficially owned by The Phoenix "nostro" accounts. 301,310 ordinary shares (representing 0.03% of the total ordinary shares outstanding) beneficially owned by The Phoenix pension and provident funds. 244,017 ordinary shares (representing 0.02% of the total ordinary shares outstanding) beneficially owned by Linked insurance policies of Phoenix. 42,168,458.20 ordinary shares (representing 3.68% of the total ordinary shares outstanding) beneficially owned by Partnership for Israeli shares (1). 91,600 ordinary shares (representing 0.01% of the total ordinary shares outstanding) beneficially owned by Partnership for investing in shares indexes (1). (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement.
(b)	Percent of class: See row 11 of cover page of each reporting person
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See row 5 of cover page of each reporting person
	(ii) Shared power to vote or to direct the vote: See row 6 of cover page of each reporting person and note in Item 4(a) above
	(iii) Sole power to dispose or to direct the disposition of: See row 7 of cover page of each reporting person
	(iv) Shared power to dispose or to direct the disposition of: See row 8 of cover page of each reporting person and note in Item 4(a) above
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Phoenix Financial Ltd.

Signature:	/s/ Eli Schwartz
Name/Title:	Vice President - Chief Financial
Date:	07/21/2025

Signature:	/s/ Haggai Schreiber
Name/Title:	Executive Vice President - Chief Investment Officer
Date:	07/21/2025

Comments accompanying signature: Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.

Exhibit Information

Exhibit 1 - Notice of resolution of the Board of Directors of Phoenix Financial Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 1, 2024).

FAQ

How many TEVA shares does Phoenix Financial own?

57,383,157.61 ordinary shares, including 38 million represented by ADSs.

What percentage of Teva’s outstanding shares does this represent?

Exactly 5.0 % based on 1,146,838,689 shares outstanding.

When did Phoenix cross the 5 % ownership threshold?

The reportable event date is 14 July 2025.

Is Phoenix Financial seeking control of Teva?

No. The filing is under Rule 13d-1(b) and explicitly states no intent to influence control.

How are the shares distributed among Phoenix subsidiaries?

Largest block is 42.17 M shares via Partnership for Israeli Shares; other holdings are split among trust funds, nostro accounts, pension/provident funds and linked policies.

Does the stake include Teva ADSs?

Yes. The total includes 38,000,044 ADSs, each representing one ordinary share.